Open-label Study of Liothyronine in MS

Phase 1

Completed

• Conditions: Multiple Sclerosis, Secondary Progressive; Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis, Primary Progressive
• Interventions: Drug: liothyronine

• Registration Number: NCT02506751
• Lead Sponsor: Johns Hopkins University

Brief Summary

This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.

Detailed Description

Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system (CNS) that is characterized by inflammation, demyelination, and neurodegeneration. It remains the most common non-traumatic cause of neurologic disability in young adults and presents in most patients as relapsing-remitting disease. Relapses, caused by inflammatory demyelination, can result in a significant amount of neurological disability and reduced health-related quality of life, and having frequent early relapses is associated with increased risk of longer-term disability. Clinical recovery from early relapses is incomplete in approximately half of patients with MS. The mechanisms underlying relapse recovery are not completely understood.

Remyelination of acutely denuded axons is one mechanism by which relapse recovery may occur. Remyelination is suspected to occur via newly differentiated oligodendrocytes, which are derived from oligodendrocyte precursor cells (OPCs) in the CNS. However, despite the presence of this innate repair mechanism, many patients go on to develop progressive functional disability. This may be due to a failure of remyelination or because of progressive axonal injury. Chronic demyelinating lesions are surrounded by OPCs and premyelinating oligodendrocytes, which suggest that failed remyelination does occur and could be partially due to incomplete oligodendrocyte differentiation. Additionally, recent studies have highlighted the importance of mitochondrial dysfunction, perhaps related to oxidative stress or increased energy demands, in mediating MS disease progression. Mitochondrial dysfunction may drive axonal degeneration with resultant neurodegeneration and progressive neurological decline (progressive MS). While numerous immune modulating therapies exist, currently, there is an urgent need for novel therapies that have neuroreparative and neuroprotective properties.

Thyroid hormones may play a direct role in remyelination and repair in the adult CNS by promoting maturation of oligodendrocytes. Further, thyroid hormones have been shown to reduce oxidative stress and thus may have the capacity to prevent mitochondrial dysfunction as well. Since tri-iodothyronine (T3) is believed to mediate the most important thyroid hormone actions, liothyronine (synthetic form of T3) has the potential to induce reparative mechanisms and limit secondary neurodegeneration in MS. In mice, T3 administration has shown to help facilitate recovery from cuprizone-induced demyelination. In this study, the investigators propose to perform a phase 1 study in patients with MS to establish a tolerable dose of liothyronine, evaluate the safety of this medication, determine whether it impacts function, and evaluate if it is associated with changes in neurotrophic and/or inflammatory biomarkers in the cerebrospinal fluid (CSF).

Study Timeline

• Study Start: 2015-07
• Study First Submitted: 2015-07-12
• Study First Submitted QC: 2015-07-21
• Study First Posted: 2015-07-23
• Primary Completion: 2017-09-18
• Study Completion: 2017-09-18
• Status Verified: 2018-02
• Last Update Submitted: 2018-02-08
• Last Update Posted: 2018-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Must meet 2010 McDonald criteria for clinically definite MS
• Must be euthyroid
• Expanded Disability Status Scale (EDSS) 3.0-7.5
• Patients may be on MS immunomodulating therapies or immunosuppressant therapies during the study

Exclusion Criteria

• Known thyroid disease (past or current)
• Currently on thyroid replacement therapy
• Steroid use within a month of screening
• History of coronary artery disease, atrial fibrillation, or other clinically significant cardiac disease
• History of adrenal insufficiency
• Ongoing renal and/or liver disease
• Ongoing severe depression and/or anxiety
• Use of carbamazepine, phenytoin, phenobarbital, warfarin, antacids, cholestyramine, colestipol, sucralfate, and rifampin
• Known contraindication to using beta-blocker medications
• History of alcohol or substance abuse in the past 6 months
• Pregnant or nursing
• If the investigator feels that participation in this study is not in the best interest of the subject

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Liothyronine	liothyronine	Subjects will take oral liothyronine for a total of 24 weeks following the below titration schedule: 0-6 weeks: liothyronine 10mcg po daily (5mcg po BID) 6-12 weeks: liothyronine 20mcg po daily (10mcg po BID) 12-18 weeks: liothyronine 50mcg po daily (25mcg po BID) 18-24 weeks: liothyronine 1mcg/kg/day (0.5mcg/kg po BID), not to exceed 75mcg po daily

Primary Outcome Measures

Name	Time	Method
The incidence rate of adverse events	26 weeks

Trial Locations

Locations (1)

The Johns Hopkins Hospital; 🇺🇸 Baltimore, Maryland, United States